Joel Ackerman's most recent trade in DaVita Inc was a trade of 16,597 Stock Appreciation Rights done . Disclosure was reported to the exchange on March 15, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| DaVita Inc | Joel Ackerman | CFO and Treasuer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2025 | 16,597 | 16,597 | - | - | Stock Appreciation Rights | |
| DaVita Inc | Joel Ackerman | CFO and Treasuer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2025 | 5,995 | 148,064 (0%) | 0% | 0 | Common Stock | |
| DaVita Inc | Joel Ackerman | CFO and Treasuer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 143.45 per share. | 15 Mar 2025 | 3,331 | 141,640 (0%) | 0% | 143.5 | 477,832 | Common Stock |
| DaVita Inc | Joel Ackerman | CFO and Treasuer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 143.45 per share. | 15 Mar 2025 | 3,093 | 144,971 (0%) | 0% | 143.5 | 443,691 | Common Stock |
| DaVita Inc | Joel Ackerman | CFO and Treasuer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Mar 2025 | 7,394 | 134,848 (0%) | 0% | 0 | Common Stock | |
| DaVita Inc | Joel Ackerman | CFO and Treasuer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Mar 2025 | 7,221 | 142,069 (0%) | 0% | 0 | Common Stock | |
| Champions Oncology Inc | Joel Ackerman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Nov 2024 | 43,190 | 43,190 | - | - | Option to purchase Common Stock | |
| Champions Oncology Inc | Joel Ackerman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2024 | 88,470 | 0 | - | - | Option to purchase Common Stock | |
| Champions Oncology Inc | Joel Ackerman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.10 per share. | 31 Oct 2024 | 88,470 | 945,467 (8%) | 0% | 2.1 | 185,787 | Common Stock |
| Champions Oncology Inc | Joel Ackerman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2024 | 16,667 | 0 | - | - | Option to purchase Common Stock | |
| Champions Oncology Inc | Joel Ackerman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.43 per share. | 31 Oct 2024 | 16,667 | 962,134 (8%) | 0% | 5.4 | 90,502 | Common Stock |
| DaVita Inc | Joel Ackerman | CFO and Treasuer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2024 | 78,999 | 0 | - | - | Stock Appreciation Rights | |
| DaVita Inc | Joel Ackerman | CFO and Treasuer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 75.95 per share. | 16 Sep 2024 | 78,999 | 185,740 (0%) | 0% | 75.9 | 5,999,974 | Common Stock |
| DaVita Inc | Joel Ackerman | CFO and Treasuer | Sale or transfer of securities back to the company at price $ 163.56 per share. | 16 Sep 2024 | 36,684 | 149,056 (0%) | 0% | 163.6 | 6,000,035 | Common Stock |
| DaVita Inc | Joel Ackerman | CFO and Treasuer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 163.56 per share. | 16 Sep 2024 | 21,602 | 127,454 (0%) | 0% | 163.6 | 3,533,223 | Common Stock |
| DaVita Inc | Joel Ackerman | CFO and Treasuer | Sale of securities on an exchange or to another person at price $ 155.06 per share. | 27 Aug 2024 | 64,029 | 111,481 (0%) | 0% | 155.1 | 9,928,586 | Common Stock |
| DaVita Inc | Joel Ackerman | CFO and Treasuer | Sale of securities on an exchange or to another person at price $ 155.02 per share. | 27 Aug 2024 | 4,740 | 106,741 (0%) | 0% | 155.0 | 734,785 | Common Stock |
| DaVita Inc | Joel Ackerman | CFO and Treasuer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2024 | 14,349 | 171,152 (0%) | 0% | 0 | Common Stock | |
| DaVita Inc | Joel Ackerman | CFO and Treasuer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2024 | 10,977 | 183,574 (0%) | 0% | 0 | Common Stock | |
| DaVita Inc | Joel Ackerman | CFO and Treasuer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 136.00 per share. | 14 Mar 2024 | 8,064 | 175,510 (0%) | 0% | 136 | 1,096,704 | Common Stock |
| DaVita Inc | Joel Ackerman | CFO and Treasuer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2024 | 1,445 | 172,597 (0%) | 0% | 0 | Common Stock | |
| DaVita Inc | Joel Ackerman | CFO and Treasuer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2024 | 55,000 | 0 | - | - | Stock Appreciation Rights | |
| DaVita Inc | Joel Ackerman | CFO and Treasuer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 52.41 per share. | 06 Mar 2024 | 55,000 | 195,360 (0%) | 0% | 52.4 | 2,882,550 | Common Stock |
| DaVita Inc | Joel Ackerman | CFO and Treasuer | Sale or transfer of securities back to the company at price $ 134.65 per share. | 06 Mar 2024 | 21,408 | 173,952 (0%) | 0% | 134.6 | 2,882,587 | Common Stock |
| DaVita Inc | Joel Ackerman | CFO and Treasuer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 134.65 per share. | 06 Mar 2024 | 17,149 | 156,803 (0%) | 0% | 134.7 | 2,309,113 | Common Stock |
| DaVita Inc | Ackerman Joel | CFO and Treasuer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 52.41 per share. | 21 Feb 2024 | 55,000 | 178,726 (0%) | 0% | 52.4 | 2,882,550 | Common Stock |
| DaVita Inc | Ackerman Joel | CFO and Treasuer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2024 | 55,000 | 55,000 | - | - | Stock Appreciation Rights | |
| DaVita Inc | Joel Ackerman | CFO and Treasuer | Sale or transfer of securities back to the company at price $ 123.00 per share. | 21 Feb 2024 | 23,436 | 155,290 (0%) | 0% | 123 | 2,882,628 | Common Stock |
| DaVita Inc | Joel Ackerman | CFO and Treasuer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 123.00 per share. | 21 Feb 2024 | 14,930 | 140,360 (0%) | 0% | 123 | 1,836,390 | Common Stock |
| Champions Oncology Inc | Joel Ackerman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Nov 2023 | 35,750 | 35,750 | - | - | Option to purchase Common Stock | |
| Champions Oncology Inc | Ackerman Joel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.10 per share. | 17 Oct 2023 | 114,552 | 856,997 (7%) | 0% | 2.1 | 240,559 | Common Stock |
| Champions Oncology Inc | Joel Ackerman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Oct 2023 | 100,000 | 0 | - | - | Option to purchase Common Stock | |
| Champions Oncology Inc | Joel Ackerman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Oct 2023 | 14,552 | 0 | - | - | Option to purchase Common Stock | |
| DaVita Inc | Joel Ackerman | CFO and Treasuer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 96.86 per share. | 15 May 2023 | 12,861 | 123,726 (0%) | 0% | 96.9 | 1,245,716 | Common Stock |
| DaVita Inc | Joel Ackerman | CFO and Treasuer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 96.86 per share. | 15 May 2023 | 7,625 | 136,587 (0%) | 0% | 96.9 | 738,558 | Common Stock |
| DaVita Inc | Joel Ackerman | CFO and Treasuer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Apr 2023 | 2,790 | 134,791 (0%) | 0% | 0 | Common Stock | |
| DaVita Inc | Joel Ackerman | CFO and Treasuer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 23,672 | 136,970 (0%) | 0% | 0 | Common Stock | |
| DaVita Inc | Joel Ackerman | CFO and Treasuer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 76.04 per share. | 15 Mar 2023 | 4,260 | 132,710 (0%) | 0% | 76.0 | 323,930 | Common Stock |
| DaVita Inc | Joel Ackerman | CFO and Treasuer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 76.04 per share. | 15 Mar 2023 | 709 | 132,001 (0%) | 0% | 76.0 | 53,912 | Common Stock |
| DaVita Inc | Joel Ackerman | CFO and Treasuer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2023 | 1,387 | 113,298 (0%) | 0% | 0 | Common Stock | |
| DaVita Inc | Joel Ackerman | CFO and Treasuer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 22,400 | 103,568 (0%) | 0% | 0 | Common Stock | |
| DaVita Inc | Joel Ackerman | CFO and Treasuer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 8,343 | 111,911 (0%) | 0% | 0 | Common Stock | |
| Champions Oncology Inc | Joel Ackerman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2022 | 26,500 | 26,500 | - | - | Option to purchase Common Stock | |
| Champions Oncology Inc | Joel Ackerman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.21 per share. | 19 Oct 2022 | 16,667 | 1,460,595 (12%) | 0% | 3.2 | 53,501 | Common Stock |
| Champions Oncology Inc | Joel Ackerman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Oct 2022 | 16,667 | 0 | - | - | Option to purchase Common Stock | |
| DaVita Inc | Joel Ackerman | CFO and Treasuer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 100.05 per share. | 15 May 2022 | 14,082 | 88,792 (0%) | 0% | 100.0 | 1,408,904 | Common Stock |
| DaVita Inc | Joel Ackerman | CFO and Treasuer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 100.05 per share. | 15 May 2022 | 9,414 | 105,749 (0%) | 0% | 100.1 | 941,871 | Common Stock |
| DaVita Inc | Joel Ackerman | CFO and Treasuer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 100.05 per share. | 15 May 2022 | 7,624 | 81,168 (0%) | 0% | 100.0 | 762,781 | Common Stock |
| DaVita Inc | Joel Ackerman | CFO and Treasuer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 100.05 per share. | 15 May 2022 | 2,875 | 102,874 (0%) | 0% | 100.1 | 287,644 | Common Stock |
| DaVita Inc | Joel Ackerman | CFO and Treasuer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Apr 2022 | 28,385 | 115,163 (0%) | 0% | 0 | Common Stock | |
| DaVita Inc | Joel Ackerman | CFO and Treasuer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Apr 2022 | 18,438 | 86,778 (0%) | 0% | 0 | Common Stock | |
| DaVita Inc | Joel Ackerman | CFO and Treasuer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2022 | 43,388 | 43,388 | - | - | Common Stock | |
| DaVita Inc | Joel Ackerman | CFO and Treasuer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Aug 2021 | 145,159 | 0 | - | - | Stock Appreciation Rights | |
| DaVita Inc | Joel Ackerman | CFO and Treasuer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 68.89 per share. | 09 Aug 2021 | 145,159 | 180,659 (0%) | 0% | 68.9 | 10,000,004 | Common Stock |
| DaVita Inc | Joel Ackerman | CFO and Treasuer | Sale or transfer of securities back to the company at price $ 133.17 per share. | 09 Aug 2021 | 75,093 | 105,566 (0%) | 0% | 133.2 | 10,000,135 | Common Stock |
| DaVita Inc | Joel Ackerman | CFO and Treasuer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 133.17 per share. | 09 Aug 2021 | 37,226 | 68,340 (0%) | 0% | 133.2 | 4,957,386 | Common Stock |
| DaVita Inc | Joel Ackerman | CFO & Treasurer | Sale of securities on an exchange or to another person at price $ 131.36 per share. | 05 Aug 2021 | 37,760 | 35,500 (0%) | 0% | 131.4 | 4,960,146 | Common Stock |
| DaVita Inc | Joel Ackerman | CFO and Treasuer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 125.41 per share. | 15 May 2021 | 11,180 | 85,707 (0%) | 0% | 125.4 | 1,402,084 | Common Stock |
| DaVita Inc | Joel Ackerman | CFO and Treasuer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 125.41 per share. | 15 May 2021 | 8,272 | 73,260 (0%) | 0% | 125.4 | 1,037,392 | Common Stock |
| DaVita Inc | Joel Ackerman | CFO and Treasuer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 125.41 per share. | 15 May 2021 | 2,756 | 82,951 (0%) | 0% | 125.4 | 345,630 | Common Stock |
| DaVita Inc | Joel Ackerman | CFO and Treasuer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 125.41 per share. | 15 May 2021 | 1,419 | 81,532 (0%) | 0% | 125.4 | 177,957 | Common Stock |
| DaVita Inc | Joel Ackerman | CFO and Treasuer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 125.41 per share. | 15 May 2021 | 712 | 96,887 (0%) | 0% | 125.4 | 89,292 | Common Stock |
| DaVita Inc | Joel Ackerman | CFO and Treasuer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Apr 2021 | 2,899 | 97,599 (0%) | 0% | 0 | Common Stock | |
| DaVita Inc | Joel Ackerman | CFO and Treasuer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Apr 2021 | 1,456 | 94,700 (0%) | 0% | 0 | Common Stock | |
| DaVita Inc | Joel Ackerman | CFO and Treasuer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2021 | 44,065 | 44,065 | - | - | Stock Appreciation Rights | |
| DaVita Inc | Joel Ackerman | CFO and Treasuer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 22,832 | 76,350 (0%) | 0% | 0 | Common Stock | |
| DaVita Inc | Joel Ackerman | CFO and Treasuer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 16,894 | 93,244 (0%) | 0% | 0 | Common Stock | |
| DaVita Inc | Joel Ackerman | CFO and Treasuer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 115.36 per share. | 19 Dec 2020 | 4,890 | 53,518 (0%) | 0% | 115.4 | 564,110 | Common Stock |
| Champions Oncology Inc | Joel Ackerman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Dec 2020 | 16,667 | 16,667 | - | - | Option to purchase Common Stock |